Adnexus

Adnexus Therapeutics, acquired by Bristol-Myers Squibb, is a biotechnology company focused on developing Adnectins, a proprietary class of targeted biologics.

These therapeutic proteins are engineered from the scaffold of human fibronectin, designed to bind to a wide range of biological targets with high affinity and specificity, similar to monoclonal antibodies but with the potential for a smaller size and more stable structure. The company's business model centered on leveraging its platform to discover and develop novel drug candidates for various therapeutic areas, particularly oncology.

By creating a pipeline of potential first-in-class protein therapeutics, Adnexus aimed to address unmet medical needs. The acquisition by Bristol-Myers Squibb integrated Adnexus's discovery platform and preclinical programs into a major pharmaceutical company's research and development engine, providing the resources to advance these novel protein therapeutics through clinical trials and towards commercialization. This strategic move highlights a common business model in the biotech industry, where smaller, specialized firms develop innovative technologies that are then acquired by larger companies for further development and market access.

Keywords: biotechnology, Adnectins, biologics, protein therapeutics, oncology, drug discovery, fibronectin, targeted therapies, pharmaceutical, preclinical programs